Sarcoidosis decisions — 2022

The Veteran's initial claim for a higher disability rating for sarcoidosis was denied. The Board found that the condition did not meet the criteria for a higher rating based on pulmonary involvement requiring systemic high dose corticosteroids or other severe manifestations.

The Board has decided that the Veteran's cataracts may be secondary to his service-connected sarcoidosis, but more evidence is needed for a definitive decision.

The Board has decided to remand the case due to insufficient medical opinion regarding the Veteran's respiratory conditions and exposure history. The VA is instructed to obtain authorization for private treatment records, provide a new VA medical opinion, and then readjudicate the issues.

The Veteran was granted a 100 percent rating for sarcoidosis with OSA effective August 20, 2015.,However, the Veteran's claim for an earlier effective date for Dependents' Educational Assistance (DEA) benefits was denied.

The Veteran's claims for increased ratings for sarcoidosis, sinusitis, and GERD are being remanded due to the need for additional development.

Your appeals have been dismissed as the Veteran has withdrawn all his pending appeals.

The Veteran's asbestosis was rated at 10% from July 24, 2015 to July 13, 2017. From July 13, 2017 onwards, the Veteran is granted a TDIU due to his service-connected disabilities preventing him from securing or following substantially gainful employment.

The Veteran's initial claim for an increased rating for sarcoid skin lesions was denied as the condition does not meet the criteria for a compensable evaluation under any applicable diagnostic code.

The Board has found that additional development is required for the Veteran's claims of sarcoidosis and asthma, including service connection for asthma secondary to sarcoidosis. The case is being remanded for further evaluation.

The Veteran's appeal for service connection for bilateral pes planus and sarcoidosis has been dismissed because the Veteran's attorney withdrew his appeals prior to a decision being made.

The Board has determined that the Veteran's sarcoidosis is related to his military service, granting service connection for this condition.

The Board denied the Veteran's claims for service connection for obstructive sleep apnea, colon cancer, and sarcoidosis due to asbestos exposure. The evidence did not establish a causal relationship between these conditions and his military service.

The Board has denied the Veteran's claim for service connection for sarcoidosis as new and relevant evidence was not received to warrant readjudication of the claim.

The Board denied service connection for a bilateral foot disorder, finding that the Veteran's current diagnosed conditions are less likely than not related to his military service.,Service connection for body pain was also denied due to lack of evidence showing causation or aggravation by sarcoidosis.

The Board has remanded the Veteran's claims for sarcoidosis and infectious hepatitis due to a lack of compliance with previous remand directives regarding VA examinations. The Veteran is advised to appear for any scheduled VA examinations.

The Board has remanded the Veteran's claim for obstructive sleep apnea, to include as secondary to service-connected sarcoidosis, due to insufficient development of evidence and failure to address whether VA satisfied its duty to assist in obtaining the Veteran's separation examination.

The Board has denied the Veteran's claims for service connection for sarcoidosis and diabetes mellitus, type II. The evidence does not support a finding that these conditions began during service or are related to in-service environmental exposures.

The Board has remanded the cases of sarcoidosis and asthma for additional development due to inadequate VA opinions.

The Board denied service connection for sarcoidosis and chronic urticaria, finding no current diagnosis or evidence of in-service disease or injury related to these conditions.

The reduction of the disability rating for service-connected sarcoidosis, lungs, history, from 10 percent to noncompensable, effective May 1, 2018, was not proper and the 10 percent rating is restored.